All product descriptions and articles provided on this website are intended strictly for informational and educational purposes. Our products are designed exclusively for in-vitro research (i.e., experiments conducted outside of a living organism, typically in glassware such as test tubes or petri dishes). These compounds are not approved by the FDA for use in humans or animals. They are not medications, nor are they intended to diagnose, treat, prevent, or cure any disease or medical condition. Any bodily administration-human or animal-is strictly prohibited by law. Our products are not for human consumption under any circumstances.
The Grow-H blend pairs a growth-hormone-releasing hormone (GHRH) analog, CJC-1295 (No DAC), with a selective ghrelin-receptor agonist, Ipamorelin. This review examines what the primary literature actually reports for each molecule in laboratory models, where the human data sit, and why the “No DAC” distinction matters when interpreting the evidence.
Key takeaways
- Grow-H combines two mechanistically distinct growth-hormone (GH) secretagogues that act on separate receptors: the GHRH receptor and the ghrelin receptor (GHS-R1a).
- In healthy adults, the long-acting DAC-conjugated version of CJC-1295 produced sustained, dose-dependent rises in GH and IGF-1; the “No DAC” variant studied here is short-acting and has far less dedicated human data.
- Ipamorelin is characterized in rodent and swine models as a selective GH secretagogue that, unlike earlier GHRPs, did not raise ACTH or cortisol in those studies.
- Combining a GHRH pathway agonist with a ghrelin-pathway agonist has shown synergistic GH release in human challenge studies of related compounds, but no controlled trial of the Grow-H combination itself is published.
- Neither peptide is an FDA-approved therapeutic; the material is supplied for laboratory research use only.
On this page
What the Grow-H blend contains
Grow-H is a two-component research formulation: 5 mg of CJC-1295 (No DAC) and 5 mg of Ipamorelin. The two molecules belong to different pharmacological classes. CJC-1295 (No DAC) is an analog of growth-hormone-releasing hormone, meaning it engages the same receptor the hypothalamus uses to instruct the pituitary to make GH. Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a ghrelin mimetic, engaging a separate receptor.5
Because the constituents act through independent receptor systems, most of the useful literature evaluates each one on its own before any combination is considered. Studying the components individually — and then asking what a combination might add — is the standard way researchers interpret a blend like this in controlled endocrine models. Investigators comparing GHRH-pathway tools may also look at single-agent analogs such as Sermorelin or Tesamorelin, while the ghrelin arm can be examined with Ipamorelin alone.
CJC-1295 (No DAC): the GHRH pathway
Endogenous GHRH is a hypothalamic peptide that binds receptors on pituitary somatotroph cells to promote the synthesis and release of GH. Its therapeutic and experimental use has always been limited by an extremely short half-life. CJC-1295 was engineered as a GHRH(1-29) analog with amino-acid substitutions that resist enzymatic breakdown, extending its duration of action relative to native GHRH.1
In a randomized, placebo-controlled, double-blind study in healthy adults aged 21–61, subcutaneous CJC-1295 produced dose-dependent increases in mean plasma GH of roughly two- to ten-fold and increases in IGF-1 of about 1.5- to three-fold, with effects persisting for several days after a single injection.1 A companion clinical study reported that this continuous GHRH-receptor stimulation raised trough and mean GH levels while preserving the pulsatile pattern of GH secretion — the frequency and magnitude of secretory pulses were unchanged, but basal GH rose markedly.2 Preserved pulsatility is a mechanistically important observation, because pulsatile signaling is thought to underlie many of GH’s downstream effects.
Proteomic work in normal adult men found that activating the GH/IGF-1 axis with CJC-1295 changed the serum protein profile, including shifts in apolipoprotein and transthyretin isoforms — further evidence that the axis was engaged at a systemic level.3 An important caveat runs through all three of these human reports, addressed in detail below: they studied the DAC-conjugated form of CJC-1295, not the “No DAC” variant.
Ipamorelin: the ghrelin-receptor pathway
The second arm of the blend works through an entirely separate system. In 1999, researchers identified ghrelin — a 28-amino-acid, octanoylated stomach peptide — as the endogenous ligand of the growth-hormone secretagogue receptor (GHS-R1a), establishing a GH-regulating pathway distinct from GHRH.7 Ipamorelin is a synthetic agonist of that same receptor.
In its founding characterization, Ipamorelin released GH from rat pituitary cells in vitro and in anesthetized rats and conscious swine with a potency and efficacy comparable to the earlier compound GHRP-6, and pharmacological profiling with antagonists confirmed it acts through a GHRP-like (ghrelin) receptor rather than the GHRH receptor.5 The defining finding was selectivity: unlike GHRP-6 and GHRP-2, Ipamorelin did not raise ACTH or cortisol above baseline even at doses more than 200-fold above its GH-releasing ED50, which is why the original authors described it as “the first selective growth hormone secretagogue.”5
A separate rodent study examined a functional readout. Administered subcutaneously three times daily for 15 days to adult female rats, Ipamorelin dose-dependently increased the longitudinal bone growth rate of the proximal tibia (from 42 to as much as 52 µm/day) and increased body-weight gain — notably without changing total IGF-1 levels or standard serum markers of bone turnover.6 That dissociation between a growth effect and unchanged IGF-1 is a useful reminder that GH-axis endpoints do not always move together.
Why two secretagogues are studied together
The rationale for combining a GHRH analog with a ghrelin-receptor agonist rests on their acting at two convergent but independent control points on the same somatotroph cell. CJC-1295 (No DAC) engages the GHRH receptor; Ipamorelin engages GHS-R1a. Because ghrelin-pathway signaling was shown to be distinct from — not redundant with — GHRH signaling, the two inputs can, in principle, be additive or synergistic rather than simply duplicative.7
Human challenge studies of the related pairing GHRP-6 plus GHRH support this logic: in normal-weight subjects and controls, combined administration elicited a synergistic GH response substantially larger than either agent alone.8 That literature is the closest published analog to the Grow-H concept. It is important to be precise about what it does and does not establish: it demonstrates synergy for GHRP-6 + GHRH in acute testing, not for the specific CJC-1295 (No DAC) + Ipamorelin combination, which has not been the subject of a published controlled trial.
What the literature actually reports
The strength and species of evidence differ markedly between the two components and between the DAC and No-DAC forms of CJC-1295. The table below summarizes the primary findings referenced in this article and the model each came from.
| Component / topic | Model | Reported finding | Evidence level |
|---|---|---|---|
| CJC-1295 (DAC form) | Healthy adults, RCT | Sustained, dose-dependent rise in GH and IGF-1 over several days1 | Human RCT (DAC version) |
| CJC-1295 (DAC form) | Healthy men, clinical study | Raised trough/mean GH with preserved pulsatility2 | Human clinical study |
| CJC-1295 (DAC form) | GHRH-knockout mice | Once-daily dosing normalized growth; somatotroph proliferation4 | Rodent, mechanistic |
| CJC-1295 (No DAC) | — | No dedicated human RCT identified; short-acting GHRH(1-29) analog | Evidence gap |
| Ipamorelin | Rat cells, rats, swine | Selective GH release; no ACTH/cortisol rise5 | Preclinical, in vitro + in vivo |
| Ipamorelin | Adult rats | Dose-dependent longitudinal bone growth; IGF-1 unchanged6 | Rodent, functional |
| GHRH + GHRP-6 | Human challenge study | Synergistic acute GH response8 | Human, analog combination |
Read together, the pattern is clear: the most robust human data attach to the DAC form of CJC-1295 and to the general principle of GHRH-plus-ghrelin synergy, while the Ipamorelin evidence is strong mechanistically but predominantly preclinical, and the specific Grow-H combination has not itself been trialed.
The DAC vs No-DAC distinction
This is the single most important interpretive point for the Grow-H blend, and it is often blurred in secondary sources. “DAC” refers to the Drug Affinity Complex — a maleimidoproprionic acid group that lets the peptide bind covalently to circulating albumin after injection, extending its estimated half-life to roughly 6–8 days. The human studies showing multi-day GH and IGF-1 elevations used this albumin-binding CJC-1295 with DAC.12
The Grow-H component is CJC-1295 without DAC. Removing the albumin-binding element leaves a modified GHRH(1-29) analog with a much shorter duration of action — pharmacologically closer to short-acting GHRH tools such as sermorelin than to the long-acting DAC conjugate. That means the sustained, days-long IGF-1 curves reported for the DAC version should not be assumed to apply to the No-DAC variant. Researchers should treat the DAC human data as informative about the GHRH-receptor mechanism in general, but not as a direct characterization of the No-DAC molecule’s pharmacokinetics. The rodent GHRH-knockout work, which showed that once-daily CJC-1295 (DAC) restored normal growth and drove somatotroph proliferation, is likewise a mechanism demonstration in an albumin-binding context.4
Limitations, gaps, and regulatory status
Evidence gaps
Three gaps deserve explicit statement. First, no published controlled trial evaluates the CJC-1295 (No DAC) + Ipamorelin combination as formulated. Second, the No-DAC form of CJC-1295 lacks the dedicated human pharmacokinetic dataset that exists for the DAC form. Third, much of the Ipamorelin evidence base is two to three decades old and rodent- or swine-derived, so extrapolation to other species or to combined dosing is speculative.56
Interpretation cautions
The Ipamorelin bone-growth study is a reminder that GH-axis endpoints can dissociate: a measurable growth effect occurred with no change in circulating IGF-1.6 Researchers designing experiments around this blend should therefore predefine which readouts they treat as primary and avoid assuming that any single marker captures pathway activation.
Material and regulatory status
Research-grade peptides can vary in purity and reconstitution behavior between batches, so identity, concentration, and handling controls matter for reproducibility. Neither CJC-1295 (No DAC) nor Ipamorelin is approved by the FDA as a therapeutic, and both are appropriate only for controlled laboratory investigation under applicable institutional and legal requirements.
Frequently asked questions
References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. https://doi.org/10.1210/jc.2005-1536
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–7. https://doi.org/10.1210/jc.2006-1702
- Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471–7. https://doi.org/10.1016/j.ghir.2009.03.001
- Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290–4. https://doi.org/10.1152/ajpendo.00201.2006
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–61. https://doi.org/10.1530/eje.0.1390552
- Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106–13. https://doi.org/10.1054/ghir.1999.9998
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–60. https://doi.org/10.1038/45230
- Micić D, Macut D, Popović V, Kendereski A, Sumarac-Dumanović M, Zorić S, Dieguez C, Casanueva FF. Growth hormone (GH) response to GH-releasing peptide-6 and GH-releasing hormone in normal-weight and overweight patients with non-insulin-dependent diabetes mellitus. Metabolism. 1999;48(4):525–30. https://doi.org/10.1016/s0026-0495(99)90115-4
All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.
